Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Suellen Marinho Andrade, Clébya Candeia de Oliveira Marques, Larissa Coutinho de Lucena, Karina Vieira da Costa, Irinaldo Capitulino de Souza, Camila Beatriz da Silva Machado, Maria Eduarda Bezerra Sales Queiroz, Larissa Pereira Costa, Stephano Tomaz da Silva
OBJECTIVE: To analyze the effects of transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS) on the cognitive function of individuals with Alzheimer's disease (AD). METHODS: This systematic review with meta-analysis and meta-regression included randomized clinical trials published until 05/2022. We included studies conducted with individuals with AD of both sexes, aged between 55 and 85 years, treated with tDCS, TMS, or both...
April 18, 2024: Neurological Research
#2
JOURNAL ARTICLE
Ahad Behboodi, Julia Kline, Andrew Gravunder, Connor Phillips, Sheridan M Parker, Diane L Damiano
In the realm of motor rehabilitation, Brain-Computer Interface Neurofeedback Training (BCI-NFT) emerges as a promising strategy. This aims to utilize an individual's brain activity to stimulate or assist movement, thereby strengthening sensorimotor pathways and promoting motor recovery. Employing various methodologies, BCI-NFT has been shown to be effective for enhancing motor function primarily of the upper limb in stroke, with very few studies reported in cerebral palsy (CP). Our main objective was to develop an electroencephalography (EEG)-based BCI-NFT system, employing an associative learning paradigm, to improve selective control of ankle dorsiflexion in CP and potentially other neurological populations...
2024: Frontiers in Human Neuroscience
#3
JOURNAL ARTICLE
Robert W Motl, Charles H Bombardier, Jennifer Duffecy, Brooks Hibner, Alison Wathen, Michael Carrithers, Gary Cutter
BACKGROUND: Major depressive disorder (MDD) is prevalent, yet sub-optimally treated among persons with multiple sclerosis (MS). We propose that exercise training may be a promising approach for treating depression in persons with MS who have MDD. Our primary hypothesis predicts a reduction in depression severity immediately after an exercise training intervention compared with minimal change in an attention control condition, and the reduction will be maintained during a follow-up period...
April 17, 2024: BMC Neurology
#4
REVIEW
Luigi Maria Chiatto, Francesco Corallo, Rocco Salvatore Calabrò, Davide Cardile, Maria Pagano, Irene Cappadona
Heart failure can lead to cognitive impairment that is estimated to be present in over a quarter of patients. It is important to intervene at a cognitive level to promote brain plasticity through cognitive training programs. Interventions transformed by technology offer the promise of improved cognitive health for heart failure patients. This review was conducted on studies evaluating the role of cognitive rehabilitation in patients with heart failure. We examined clinical trials involving patients with heart failure...
April 17, 2024: Neurological Sciences
#5
JOURNAL ARTICLE
Hyun Wook Yang, A Ra Kho, Song Hee Lee, Beom Seok Kang, Min Kyu Park, Chang Jun Lee, Se Wan Park, Seo Young Woo, Dong Yeon Kim, Hyun Ho Jung, Bo Young Choi, Won Il Yang, Hong Ki Song, Hui Chul Choi, Jin Kyu Park, Sang Won Suh
Epilepsy, a complex neurological disorder, is characterized by recurrent seizures caused by aberrant electrical activity in the brain. Central to this study is the role of lysosomal dysfunction in epilepsy, which can lead to the accumulation of toxic substrates and impaired autophagy in neurons. Our focus is on phosphodiesterase-4 (PDE4), an enzyme that plays a crucial role in regulating intracellular cyclic adenosine monophosphate (cAMP) levels by converting it into adenosine monophosphate (AMP). In pathological states, including epilepsy, increased PDE4 activity contributes to a decrease in cAMP levels, which may exacerbate neuroinflammatory responses...
April 16, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
#6
REVIEW
Irene Cortese, Gina Norato, Patrick R Harrington, Therri Usher, Ilaria Mainardi, Guillaume Martin-Blondel, Paola Cinque, Eugene O Major, Virginia Sheikh
Progressive multifocal leukoencephalopathy is a rare but devastating demyelinating disease caused by the JC virus (JCV), for which no therapeutics are approved. To make progress towards addressing this unmet medical need, innovations in clinical trial design are needed. Quantitative JCV DNA in CSF has the potential to serve as a valuable biomarker of progressive multifocal leukoencephalopathy disease and treatment response in clinical trials to expedite therapeutic development, as do neuroimaging and other fluid biomarkers such as neurofilament light chain...
May 2024: Lancet Neurology
#7
JOURNAL ARTICLE
Julie K Wisch, Nicole S McKay, Anna H Boerwinkle, James Kennedy, Shaney Flores, Benjamin L Handen, Bradley T Christian, Elizabeth Head, Mark Mapstone, Michael S Rafii, Sid E O'Bryant, Julie C Price, Charles M Laymon, Sharon J Krinsky-McHale, Florence Lai, H Diana Rosas, Sigan L Hartley, Shahid Zaman, Ira T Lott, Dana Tudorascu, Matthew Zammit, Adam M Brickman, Joseph H Lee, Thomas D Bird, Annie Cohen, Patricio Chrem, Alisha Daniels, Jasmeer P Chhatwal, Carlos Cruchaga, Laura Ibanez, Mathias Jucker, Celeste M Karch, Gregory S Day, Jae-Hong Lee, Johannes Levin, Jorge Llibre-Guerra, Yan Li, Francisco Lopera, Jee Hoon Roh, John M Ringman, Charlene Supnet-Bell, Christopher H van Dyck, Chengjie Xiong, Guoqiao Wang, John C Morris, Eric McDade, Randall J Bateman, Tammie L S Benzinger, Brian A Gordon, Beau M Ances
BACKGROUND: In people with genetic forms of Alzheimer's disease, such as in Down syndrome and autosomal-dominant Alzheimer's disease, pathological changes specific to Alzheimer's disease (ie, accumulation of amyloid and tau) occur in the brain at a young age, when comorbidities related to ageing are not present. Studies including these cohorts could, therefore, improve our understanding of the early pathogenesis of Alzheimer's disease and be useful when designing preventive interventions targeted at disease pathology or when planning clinical trials...
May 2024: Lancet Neurology
#8
JOURNAL ARTICLE
Rabi Tawil, Kathryn R Wagner, Johanna I Hamel, Doris G Leung, Jeffrey M Statland, Leo H Wang, Angela Genge, Sabrina Sacconi, Hanns Lochmüller, David Reyes-Leiva, Jordi Diaz-Manera, Jorge Alonso-Perez, Nuria Muelas, Juan J Vilchez, Alan Pestronk, Summer Gibson, Namita A Goyal, Lawrence J Hayward, Nicholas Johnson, Samantha LoRusso, Miriam Freimer, Perry B Shieh, S H Subramony, Baziel van Engelen, Joost Kools, Olof Dahlqvist Leinhard, Per Widholm, Christopher Morabito, Christopher M Moxham, Diego Cadavid, Michelle L Mellion, Adefowope Odueyungbo, William G Tracewell, Anthony Accorsi, Lucienne Ronco, Robert J Gould, Jennifer Shoskes, Luis Alejandro Rojas, John G Jiang
BACKGROUND: Facioscapulohumeral muscular dystrophy is a hereditary progressive myopathy caused by aberrant expression of the transcription factor DUX4 in skeletal muscle. No approved disease-modifying treatments are available for this disorder. We aimed to assess the safety and efficacy of losmapimod (a small molecule that inhibits p38α MAPK, a regulator of DUX4 expression, and p38β MAPK) for the treatment of facioscapulohumeral muscular dystrophy. METHODS: We did a randomised, double-blind, placebo-controlled phase 2b trial at 17 neurology centres in Canada, France, Spain, and the USA...
May 2024: Lancet Neurology
#9
JOURNAL ARTICLE
Keri S Kim, Leonard Polizzotto, Jose I Suarez, DaiWai M Olson, J Claude Hemphill, Shraddha Mainali
The Curing Coma Campaign (CCC) and its contributing collaborators identified multiple key areas of knowledge and research gaps in coma and disorders of consciousness (DoC). This step was a crucial effort and essential to prioritize future educational and research efforts. These key areas include defining categories of DoC, assessing DoC using multimodal approach (e.g., behavioral assessment tools, advanced neuroimaging studies), discussing optimal clinical trials' design and exploring computational models to conduct clinical trials in patients with DoC, and establishing common data elements to standardize data collection...
April 17, 2024: Seminars in Neurology
#10
Eva Joëlle Haasdijk, Yasmin Sadigh, Gizem Yildirim, Ruben Dammers, Victor Volovici
BACKGROUND: Limb-shaking transient ischemic attack (LSTIA) is a rare neurological condition which presents with involuntary jerky movements of the arm or leg, often because of carotid stenosis or occlusion. Due to the rarity of the condition, the epidemiology of LSTIA is poorly understood and the disease is frequently misdiagnosed. There is no standard treatment to date. The purpose of this study is to provide an overview of the epidemiology of LSTIA and its current treatment options...
April 17, 2024: Neuroepidemiology
#11
JOURNAL ARTICLE
Etienne Fortanier, Marc Adrien Hostin, Constance Michel, Emilien Delmont, Marc-Emmanuel Bellemare, Maxime Guye, David Bendahan, Shahram Attarian
BACKGROUND AND OBJECTIVES: Intramuscular fat fraction (FF) assessed using quantitative MRI (qMRI) has emerged as one of the few responsive outcome measures in CMT1A suitable for future clinical trials. This study aimed to identify the relevance of multiple qMRI biomarkers for tracking longitudinal changes in CMT1A and to assess correlations between MRI metrics and clinical parameters. METHODS: qMRI was performed in CMT1A patients at 2 time points, a year apart, and various metrics were extracted from 3-dimensional volumes of interest at thigh and leg levels...
May 14, 2024: Neurology
#12
JOURNAL ARTICLE
Lindsay McAlpine, Adeel S Zubair, Phillip Joseph, Serena Spudich
OBJECTIVES: To report a case-control study of new-onset small fiber neuropathy (SFN) after COVID-19 with invasive cardiopulmonary exercise testing (iCPET). SFN is a critical objective finding in long COVID and amenable to treatment. METHODS: A retrospective chart review was conducted on patients seen in the NeuroCOVID Clinic at Yale who developed new-onset SFN after a documented COVID-19 illness. We collected demographics, symptoms, skin biopsy, iCPET testing, treatments, and clinical response to treatment or no intervention...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
#13
REVIEW
Andreas Wolff, Antonia Franziska Demleitner, Emily Feneberg, Paul Lingor
BACKGROUND: With the increasing development of disease-modifying causative treatment, the importance of early diagnosis and detection of asymptomatic or oligosymptomatic early stages of neurodegenerative diseases is increasing. OBJECTIVE: Presentation of early stages of neurodegenerative diseases, diagnostic procedures for the early detection and possible treatment consequences. MATERIAL AND METHODS: Selective literature search, discussion of basic research and expert recommendations...
April 17, 2024: Der Nervenarzt
#14
JOURNAL ARTICLE
F-T Lee, L Sun, A Szabo, N Milligan, A Saini, D Chetan, J-L Hunt, C K Macgowan, L Freud, E Jaeggi, T Van Mieghem, J Kingdom, S P Miller, M Seed
OBJECTIVES: Fetuses with single ventricle physiology (SVP) exhibit reductions in fetal cerebral oxygenation with associated delays in fetal brain growth and neurodevelopmental outcomes. Maternal supplemental oxygen (MSO) has been proposed to improve fetal brain growth but current evidence on dosing, candidacy, and outcomes are limited. In this pilot study, we evaluated the safety and feasibility of continuous low-dose MSO in the setting of SVP. METHODS: This single-centre, open-label, pilot phase 1 safety and feasibility clinical trial included 25 pregnant individuals with a fetal diagnosis of SVP...
April 17, 2024: Ultrasound in Obstetrics & Gynecology
#15
REVIEW
Hans-Peter Müller, Jan Kassubek
Neuroimaging biomarkers have shown high potential to map the disease processes in the application to neurodegenerative diseases (NDD), e.g., diffusion tensor imaging (DTI). For DTI, the implementation of a standardized scanning and analysis cascade in clinical trials has potential to be further optimized. Over the last few years, various approaches to improve DTI applications to NDD have been developed. The core issue of this review was to address considerations and limitations of DTI in NDD: we discuss suggestions for improvements of DTI applications to NDD...
2024: Frontiers in Human Neuroscience
#16
Shuyu Ren, Fangfang Pan, Jie Jin
BACKGROUND: Alzheimer's disease (AD) is the most prevalent type of dementia and represents 60-80% of dementia cases. AD affects over 32 million people globally, and 8.1% of affected females and 5.4% of affected males were older than 65 years. Cognitive rehabilitation focuses on helping patients develop individualized strategies to obtain or maintain optimal functioning. As of now, there is no complete and systematic meta-analysis on the effects of cognitive rehabilitation on cognitive functioning in AD patients...
2024: Frontiers in Neurology
#17
JOURNAL ARTICLE
Ran Li, Sihan Liu, Tianyuan Li, Kun Yang, Xue Wang, Wenjiao Wang
BACKGROUND: The recovery of upper extremity motor impairment after stroke remains a challenging task. The clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS), which is believed to aid in the recovery process, is still uncertain. METHODS: A systematic search was conducted in Medline (Ovid), Cochrane and Embase electronic databases from March 28, 2014, to March 28, 2023. The inclusion criteria consisted of randomized controlled trials that assessed the effects of rTMS on the recovery of upper limb motor impairment among stroke patients...
2024: Frontiers in Neurology
#18
JOURNAL ARTICLE
Shalvi Mahajan, Tanavi Sharma, Nidhi Bidyut Panda, Rajeev Chauhan, Steve Joys, Nanish Sharma, Manju Mohanty, Navneet Singla, Sanjay Kumar, Ashok Kumar, Hemant Bhagat
BACKGROUND: Following aneurysmal subarachnoid hemorrhage, 40-50% of survivors experience cognitive dysfunction, which affects their quality of life. Anesthetic agents play a pivotal role in aneurysm surgeries. However, substantial evidence regarding their effects on neurocognitive function is lacking. This study evaluated the effects of propofol and desflurane on postoperative neurocognitive function and serum S-100B levels. METHODS: One hundred patients were equally randomized to receive either propofol (Group P) or desflurane (Group D)...
2024: Surgical Neurology International
#19
JOURNAL ARTICLE
Alessandro Pezzini, Barbara Tarantino, Marialuisa Zedde, Simona Marcheselli, Giorgio Silvestrelli, Alfonso Ciccone, Maria Luisa DeLodovici, Lucia Princiotta Cariddi, Simone Vidale, Maurizio Paciaroni, Cristiano Azzini, Marina Padroni, Massimo Gamba, Mauro Magoni, Massimo Del Sette, Rossana Tassi, Ivo Giuseppe De Franco, Anna Cavallini, Rocco Salvatore Calabrò, Manuel Cappellari, Elisa Giorli, Giacomo Giacalone, Corrado Lodigiani, Mara Zenorini, Francesco Valletta, Gianni Cutillo, Guido Bonelli, Giorgia Abrignani, Paola Castellini, Antonio Genovese, Lilia Latte, Maria Claudia Trapasso, Chiara Ferraro, Francesco Piancatelli, Rosario Pascarella, Ilaria Grisendi, Federica Assenza, Manuela Napoli, Claudio Moratti, Maurizio Acampa, Mario Grassi
INTRODUCTION: It is unclear which patients with non-traumatic (spontaneous) intracerebral haemorrhage (ICH) are at risk of developing acute symptomatic seizures (provoked seizures occurring within the first week after stroke onset; early seizures, ES) and whether ES predispose to the occurrence of remote symptomatic seizures (unprovoked seizures occurring more than 1 week after stroke; post-stroke epilepsy, PSE) and long-term mortality. PATIENTS AND METHODS: In the setting of the Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy) we examined the risk of ES and whether they predict the occurrence of PSE and all-cause mortality in a cohort of patients with first-ever spontaneous ICH and no previous history of epilepsy, consecutively hospitalized in 12 Italian neurological centers from 2002 to 2014...
April 16, 2024: European Stroke Journal
#20
RANDOMIZED CONTROLLED TRIAL
Daniel Rob, Klaudia Farkasovska, Marketa Kreckova, Ondrej Smid, Petra Kavalkova, Jaromir Macoun, Michal Huptych, Petra Havrankova, Juraj Gallo, Jan Pudil, Milan Dusik, Stepan Havranek, Ales Linhart, Jan Belohlavek
BACKGROUND: Randomized data evaluating the impact of the extracorporeal cardiopulmonary resuscitation (ECPR) approach on long-term clinical outcomes in patients with refractory out-of-hospital cardiac arrest (OHCA) are lacking. The objective of this follow-up study was to assess the long-term clinical outcomes of the ECPR-based versus CCPR approach. METHODS: The Prague OHCA trial was a single-center, randomized, open-label trial. Patients with witnessed refractory OHCA of presumed cardiac origin, without return of spontaneous circulation, were randomized during ongoing resuscitation on scene to conventional CPR (CCPR) or an ECPR-based approach (intra-arrest transport, ECPR if ROSC is not achieved prehospital and immediate invasive assessment)...
April 16, 2024: Critical Care: the Official Journal of the Critical Care Forum
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
